Next-Generation Targeted Protein Degradation: Beyond Classical PROTACs

Targeted protein degradation (TPD) has reshaped modern drug discovery by shifting the paradigm from occupancy-driven pharmacology to event-driven pharmacology. Rather than inhibiting protein function through sustained binding, degraders trigger the removal of disease-driving proteins from the cell entirely. This catalytic mode of action enables suppression of scaffolding proteins, transcription factors, and other historically “undruggable” targets.

First-generation PROTACs (proteolysis-targeting chimeras) demonstrated that small molecules can recruit E3 ubiquitin ligases to a target protein, inducing ubiquitination and proteasomal degradation. Clinical progress in oncology validated the approach. However, the field has rapidly evolved beyond classical PROTAC architectures.

Today’s next-generation modalities expand induced proximity in multiple dimensions:

• Context-dependent proximity (RIPTACs)
• Targeted protein stabilization (DUBTACs)
• Light-controlled degraders (PHOTACs, pcPROTACs)
• Virus-inspired proximity systems (VIPER-TACs)
• Antibody-delivered degraders (PROxAb)

Collectively, these approaches redefine TPD as a broader class of induced proximity therapeutics. The future is no longer just about degradation — it is about programmable control of protein fate, function, and location.

RIPTACs bind:

• A broadly expressed essential protein
• A tumor-restricted or overexpressed protein

By forcing proximity, the essential protein becomes functionally inactivated — but only in cells expressing the tumor-specific partner. This produces synthetic-lethal-like selectivity without directly targeting mutated genes.

Many essential proteins are poor therapeutic targets due to systemic toxicity. RIPTACs introduce a spatial and contextual filter: only cells co-expressing both proteins are affected.

This approach offers:

• Precision oncology selectivity
• Potential activity against non-mutated drivers
• Reduced reliance on enzymatic inhibition

While most proximity-based drugs remove proteins, DUBTACs (Deubiquitinase-Targeting Chimeras) reverse this logic.

DUBTACs recruit a deubiquitinase (DUB) to a ubiquitinated target protein. This removes ubiquitin chains and rescues the protein from degradation.

Many diseases arise from insufficient protein levels:

• Tumor suppressor loss
• Haploinsufficiency disorders
• Misfolding-related degradation

Instead of inhibiting E3 ligases globally (which risks toxicity), DUBTACs localize deubiquitination to a specific protein.

• Stabilizing mutant but functional tumor suppressors
• Correcting degradation-prone variants
• Potential rare disease interventions

• DUB selectivity and off-target deubiquitination
• Achieving productive ternary complexes
• Avoiding interference with endogenous ubiquitin signaling

DUBTACs demonstrate that induced proximity is not inherently degradative — it can restore function.

Precision control is an emerging frontier. Light-responsive degraders introduce temporal and spatial specificity.

PHOTACs incorporate photoswitchable moieties (e.g., azobenzene-like systems) that toggle between active and inactive conformations upon light exposure.

This allows:

• Reversible activation
• Localized degradation
• Dynamic pathway interrogation

Potential applications include neuroscience and developmental biology, where temporal control is critical.

Photocaged PROTACs remain inactive until light exposure removes a blocking group. Unlike PHOTACs, activation is typically irreversible.

• Clean on/off state
• Reduced systemic activity
• High spatiotemporal precision

These systems extend light control beyond degradation into proximity-driven signaling or reversible protein complex formation.

Rather than simply removing proteins, they allow:

• Light-triggered protein assembly
• Signal rewiring
• Controlled functional modulation

Collectively, these technologies move TPD toward precision pharmacology.

• Distinct substrate preferences
• Unique regulatory interfaces
• Potential to target proteins inaccessible to canonical ligases

• Antiviral therapies
• Immune modulation
• Novel substrate scope expansion

The challenge lies in specificity and safety — viral machinery must be carefully engineered to avoid unintended degradation.

One of the major limitations of small-molecule degraders is systemic exposure and tissue distribution. PROxAb platforms combine:

• Targeting antibodies
• Cleavable linkers
• Intracellular degrader payloads

1. Antibody binds a cell-surface antigen
2. Complex internalizes
3. Linker cleaves intracellularly
4. Released PROTAC engages intracellular target

This approach mirrors antibody-drug conjugates (ADCs), but instead of cytotoxic payloads, the cargo is a degrader.

• Cell-type specificity
• Reduced systemic toxicity
• Expanded therapeutic window

• Endosomal escape efficiency
• Linker stability
• Drug-to-antibody ratio optimization

PROxAb represents convergence between biologics and TPD.

Despite architectural diversity, common design rules apply.

Productive proximity requires:

• Favorable protein-protein interactions
• Proper geometry
• Dynamic stability

Cooperative ternary complex formation often predicts degradation efficiency better than binary binding affinity.

Choice of recruited partner dictates:

• Tissue specificity
• Resistance pathways
• Safety profile

Emerging strategies expand beyond CRBN and VHL to tissue-restricted ligases.

Linkers determine:

• Flexibility vs rigidity
• Orientation of interacting surfaces
• Cellular permeability

Structure-guided design and AI modeling increasingly guide optimization.

Next-generation systems incorporate:

• Tumor-restricted expression
• Light activation
• Antibody delivery
• Conditional engagement

Selectivity is shifting from binding specificity to biological context specificity.

Targeted protein degradation has moved from conceptual novelty to clinical reality, particularly in oncology. Next-generation modalities aim to address:

• Solid tumor resistance
• Central nervous system delivery
• Rare genetic disorders
• Immune modulation

Several biotech companies are now expanding pipelines into:

• Tissue-restricted ligase discovery
• Autophagy-based degradation
• RNA-targeted proximity systems

As the field matures, differentiation increasingly depends on:

• Ligase access
• Conditional control
• Safety margins
• Novel substrate space

Resistance mechanisms include:

• E3 ligase downregulation
• Target mutation
• Adaptive rewiring
• Proteostasis compensation

Next-generation platforms attempt to preempt resistance through:

• Alternative ligases
• Conditional activation
• Multi-target strategies

Combinatorial proximity drugs may represent a future frontier.

The evolution of targeted protein degradation reveals a broader principle: drug discovery is becoming programmable biology.

Future directions include:

• Multi-functional chimeras that degrade one protein while stabilizing another
• Tissue-restricted ligase atlases
• AI-designed ternary complexes
• Integration with synthetic lethality frameworks
• Expansion beyond proteins to RNA and chromatin complexes

Ultimately, induced proximity is not a single modality — it is a design philosophy.

The next decade will likely see:

• More precise control
• Broader target classes
• Increased integration with biologics
• Spatial and temporal programmability

Targeted protein degradation began as a clever workaround for undruggable proteins. It is now evolving into a foundational technology platform capable of reshaping therapeutic intervention at a systems level.

The era beyond classical PROTACs has begun — and it is defined not by degradation alone, but by the controlled orchestration of molecular proximity.